We are live on ! Find out more
IMUX icon

Immunic
IMUX

51 hedge funds and large institutions have $51M invested in Immunic in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 2

291% more capital invested

Capital invested by funds: $13M → $51M (+$38M)

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

143% more funds holding

Funds holding: 21 → 51 (+30)

0.8% more ownership

Funds ownership: 2.01% → 2.81% (+0.8%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
51
Holders Change
+30
Holders Change %
+142.86%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
32
Increased
10
Reduced
4
Closed
2
Calls
$676K
Puts
–
Net Calls
+$676K
Net Calls Change
+$343K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.41M
2
GPCM
Granite Point Capital Management
Massachusetts
+$2.01M
3
BlackRock
BlackRock
New York
+$1.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.78M
5
CH
CVI Holdings
Delaware
+$1.66M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$305K
2
Millennium Management
Millennium Management
New York
-$61K
3
UBS Group
UBS Group
Switzerland
-$21.8K
4
TRCT
Tower Research Capital (TRC)
New York
-$9.77K
5
Victory Capital Management
Victory Capital Management
Texas
-$8K

IMUX Hedge Fund Activity: Q2 2020 in Review

51 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2020, worth a combined $51M — up 291% from $13M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new IMUX positions and 2 closed out — a net gain of 30 holders — while 10 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.41M. The largest seller was Artal Group, cutting an estimated $305K.

  • 51 institutional investors held Immunic (IMUX) as of Q2 2020, up from 21 in Q1 2020.
  • Funds reported $51M of Immunic stock for Q2 2020, up 291% quarter-over-quarter.
  • 32 funds opened new Immunic positions in Q2 2020 and 2 closed out, a net change of +30 holders.
  • The largest Immunic buyer in Q2 2020 was Vanguard Group, an estimated $2.41M added.
  • The largest Immunic seller in Q2 2020 was Artal Group, an estimated $305K sold.

Based on aggregated 13F filings for Q2 2020.